MDNAF Stock Latest News
Company AnnouncementsMedicenna’s MDNA209 Shows Strong CD122 Blockade and Survival Gains in Autoimmune Preclinical Models6d ago
Company AnnouncementsMedicenna to Showcase CD122 Superantagonist MDNA209 Data at Paris Immunotherapy Meeting1w ago
Company AnnouncementsMedicenna Shareholders Back Board, Auditor and Potential Share Consolidation Plan1M ago
Company AnnouncementsMedicenna to Present New Bizaxofusp Survival Data in Recurrent Glioblastoma at SNO 20261M ago- Company AnnouncementsMedicenna to Spotlight Superkine Pipeline at H.C. Wainwright Global Investment Conference1M ago
Company AnnouncementsMedicenna Advances Superkine Pipeline With New Data and Regulatory Plans2M ago
Company AnnouncementsMedicenna to Highlight MDNA113 Data at 2026 Bloom Burton Healthcare Investor Conference6M ago
Company AnnouncementsMedicenna Taps Pembrolizumab Veteran as CMO to Steer Superkine Immunotherapy Pipeline6M ago- Company AnnouncementsMedicenna to Showcase First-in-Class Tumor-Targeted PD-1 x IL-2 Superkine at AACR 20267M ago
Company AnnouncementsMedicenna to Spotlight Superkine Oncology Pipeline at Global Investor and Scientific Conferences8M ago
Company AnnouncementsMedicenna Refreshes Board With Capital Markets and Biotech Leadership Expertise8M ago
Pre-EarningsMDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?8M ago- Company AnnouncementsMedicenna Maps 2026 Milestones as IL-2 Superkine MDNA11 Delivers Promising Cancer Responses9M ago
Company AnnouncementsMedicenna Targets Pivotal 2026 as IL-2 Superkine Programs Advance Toward Registrational Trials9M ago
